Clinical trials: Proteins
Multiple Myeloma and Plasma Cell Neoplasm
Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Enzyme products such as Wobe-Mugos E may help to reduce the side effects of multiple myeloma therapy.
- Trial name
- NCT00014339
- Testing
- Wobe-Mugos E, melphalan, prednisone
- Where
- 19 sites in United States
- Sponsor
- Medsearch
Malignant Peripheral Nerve Sheath Tumors (MPNST), Sarcoma
SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)
Phase 1: To assess the safety, tolerability, and maximum tolerated dose (MTD)/ recommended dose of ganetespib when administered in combination with sirolimus in patients with refractory or relapsed sarcomas including unresectable…
- Trial name
- NCT02008877
- Testing
- ganetespib, Sirolimus
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Healthy
A Study to Assess the Effects of 2 Different Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban in Healthy Adult Volunteers
The purpose of this study is to assess the use of 2 different Prothrombin Complex Concentrates (PCCs) on their ability to reverse (normalize) the pharmacodynamic effects of rivaroxaban in healthy adult volunteers.
- Trial name
- NCT01656330
- Testing
- Rivaroxaban 20 mg twice daily, Rivaroxaban 20 mg once daily, Profilnine SD
- Where
- Belgium
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Esophageal Squamous Cell Carcinoma
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
This is a Phase 1/2, multicenter, randomized, open-label umbrella platform study to evaluate the safety and efficacy of investigational agents with or without pembrolizumab and/or chemotherapy, for the treatment of participants…
- Trial name
- NCT05319730
- Testing
- Paclitaxel, Irinotecan, Pembrolizumab
- Where
- 58 sites in United States, Brazil and 12 more
- Volunteers
- 230 people
- Sponsor
- Merck Sharp & Dohme LLC
Hemophilia A
Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A
This study is to generate qualitative data to evaluate the impact of frequency of FVIII infusions on patients' satisfaction with treatment and their quality of life.
- Trial name
- NCT02971930
- Testing
- BAY94-9027
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Bayer
Lymphoma
Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma
This is a phase I, open-label, dose-escalation study of CUDC-427 in patients with advanced or refractory solid tumors or lymphoma.
- Trial name
- NCT01908413
- Testing
- CUDC-427
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Curis, Inc.
Multiple Myeloma
Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to test a new drug called carfilzomib. It is a type of drug called a proteasome inhibitor. Proteasome breaks down proteins that are no longer useful to the cell.
- Trial name
- NCT01351623
- Testing
- Carfilzomib
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer of Unknown Primary
Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary
The aim of the study is to test if a new radionuclide therapy, called 177-Lu-FAP-2286, works to treat cancer in patients with Cancer of Unknown Primary (CUP).
- Trial name
- Lu-FAP CUP (NCT07434180)
- Testing
- 177Lu-FAP-2286
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)
A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body
This study will be an open-label, fixed sequence study in healthy subjects (vasectomized males and females of non-childbearing potential), performed at a single study centre.
- Trial name
- NCT04712396
- Testing
- Capivasertib, Itraconazole
- Where
- Germany
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Allergy
Acceptability and Palatability Study of Paediatric Amino Acid Feed
Product acceptability and palatability data from a minimum of 15 participants are required to submit an application to the Advisory Committee on Borderline Substances (ACBS) and the Health Service Executive (HSE) for Ireland for…
- Trial name
- NCT06547346
- Testing
- Alfamino Junior
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Société des Produits Nestlé (SPN)
Risk of Malnutrition
Plant-based Versus Animal-based Oral Nutritional Supplements
Background information: Many people who are admitted to the hospital are at risk of malnutrition. In some patient groups, this can be as high as 40%.
- Trial name
- PAVOS (NCT07399886)
- Testing
- Fresubin Plant-based drink vanilla©, Fresubin Yodrink raspberry©
- Where
- 2 sites in Netherlands
- Volunteers
- 60 people
- Sponsor
- Radboud University Medical Center
Bleeding Disorder, Hypofibrinogenemia; Acquired
Adjusted Fibrinogen Replacement Strategy
The main purpose of this study was to demonstrate the efficacy and safety of intraoperative use of fibrinogen concentrate BT524, as a complementary therapy for the management of uncontrolled severe hemorrhage in acquired…
- Trial name
- AdFIrst (NCT03444324)
- Testing
- BT524, FFP/Cryo
- Where
- 19 sites in Belgium, Czechia and 5 more
- Volunteers
- 222 people
- Sponsor
- Biotest
Poor Nutrition
Acceptability and Tolerance of a Protein and Micronutrient Fortified Food
Acceptability and tolerance of a new food product in adults and children.
- Trial name
- NCT03041103
- Testing
- Food Product 1
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Chronic Kidney Disease(CKD), Metabolic Acidosis
PLADO for Conservative Management of CKD
The goal of this clinical trial is to learn if a plant-dominant low protein diet, referred to as PLADO diet, works to decrease metabolic acidosis, a major risk factor for chronic kidney disease (CKD) progression, in adults with…
- Trial name
- NCT06932042
- Testing
- PLADO, Standard-of-care diet
- Where
- Lebanon
- Volunteers
- 48 people
- Sponsor
- Lebanese American University
Proteins
Bioavailability of Protein and Amino Acids of Pea Protein Isolate in Healthy Volunteers
The study aims to determine in healthy subjects the bioavailability of protein and amino acids of pea protein isolate and casein isolate. For this purpose, the investigators will compare two methods: 1.
- Trial name
- Qualipois (NCT04072770)
- Testing
- Pea, Casein
- Where
- France
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
Retinitis Pigmentosa
Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO)
This research study is being done to learn what effect 12 months of treatment with oral hydroxychloroquine (HCQ) will have on the retina in people with retinitis pigmentosa (RP).
- Trial name
- NCT04120883
- Testing
- Hydroxychloroquine lower dose, Hydroxychloroquine higher dose
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Michigan
Glucose Metabolism, Lipid Metabolism
Effects of 10-gram Collagen Protein Hydrolysate on Cardiometabolic Health
The effects of a 10g/day collagen hydrolysate for a period of 4 weeks on glycemic control and cardiovascular health in a parallel design study using overweight/ obese men and women who are likely to have a disturbed lipid and…
- Trial name
- NCT05282641
- Testing
- 10 g of collagen hydrolysate
- Where
- Netherlands
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Multiple Myeloma
Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and Dexamethasone
Purpose of this non-interventional study is the documentation of efficacy and safety data of multiple myeloma therapy with a combined treatment of Lenalidomide and Dexamethasone in daily routine practice.
- Trial name
- REVLIMID-NIS (NCT00911105)
- Where
- 20 sites in Germany
- Volunteers
- 101 people
- Sponsor
- iOMEDICO AG
Tuberculosis, HIV
PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia
Background: Tuberculosis (TB) is a health threat for people living with human immunodeficiency virus (HIV). People living with HIV are more likely than others to develop active TB. Also, TB makes HIV progress faster.
- Trial name
- NCT04926922
- Where
- 5 sites in United States, Liberia
- Volunteers
- 200 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hemophilia
KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia
This study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of multiple subcutaneous doses of KN057 in subjects with hemophilia A or B, with or without inhibitors to Factor VIII…
- Trial name
- NCT05421429
- Testing
- KN057 doseⅠ, KN057 dose Ⅱ, KN057 dose Ⅲ
- Where
- 2 sites in China
- Volunteers
- 24 people
- Sponsor
- Suzhou Alphamab Co., Ltd.